Physician profile
Anna Wenter
NPI 1063115335
$2,779.21
in general payments reported to CMS, 2019-2025
33 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $416 · 2024: $785 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.46 |
| Education | $198.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $299.19 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $254.55 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $237.35 | 2023-2025 | |
| Pfizer INC. | $185.69 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $142.79 | 2023-2025 | Keytruda, Lynparza |
| Incyte Corporation | $134.97 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $125.05 | 2024-2025 | Tecentriq, Itovebi, Venclexta |
| Lilly USA, LLC | $116.49 | 2023-2025 | Jaypirca, Verzenio, Mounjaro |
| Sobi, INC | $106.58 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Abbvie INC. | $82.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.41 | 2025 | Ninlaro, Iclusig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.50 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $78.04 | 2024-2025 | Ultomiris |
| Array Biopharma INC | $72.71 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $69.25 | 2024-2025 | Xospata, Vyloy |
| Adaptive Biotechnologies Corporation | $59.20 | 2024-2025 | Clonoseq |
| Glaxosmithkline, LLC. | $55.16 | 2025 | Ojjaara, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $53.54 | 2023-2025 | |
| Tersera Therapeutics LLC | $53.43 | 2023-2024 | Zoladex |
| Janssen Biotech, INC. | $50.13 | 2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $42.58 | 2024-2025 | Enhertu |
| Beigene USA, INC. | $42.22 | 2024 | Brukinsa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.01 | 2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $39.20 | 2024-2025 | Libtayo |
| Exelixis INC. | $36.03 | 2025 | Cabometyx |
| Caris Mpi, INC. | $30.56 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $22.32 | 2025 | Reblozyl |
| Emd Serono, INC. | $19.62 | 2025 | |
| Beone Medicines USA, INC. | $19.50 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $18.75 | 2024 | |
| Eisai INC. | $17.95 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.58 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.